ERBB2 and neoplasm: Within the POAI group, 79% of LumB (59/75) and 14% of HER2-E (13/91) were reclassified as LumA during treatment, while the majority of LumA tumours (93%, 41/44) at baseline maintained their classification (Fig. 3a and c).